4SC AG

Industry · 13 registered clinical trials.

Status	Trial	Phase	Started
Withdrawn	Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (M Merkel Cell Carcinoma	Phase 2	2021-11-01
Completed	A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome	Phase 1	2021-10-12
Completed	Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti- Merkel Cell Carcinoma	Phase 2	2020-10-13
Completed	4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 The Malignant Melanoma	Phase 1 / Phase 2	2017-09-25
Completed	Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrom Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous	Phase 2	2016-11-01
Completed	Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) Advanced Hematologic Malignancies	Phase 1	2011-03-01
Completed	4SC-201 (Resminostat) in Advanced Colorectal Carcinoma Advanced Colorectal Carcinoma	Phase 1 / Phase 2	2011-01-01
Completed	Single Dose Study With 4SC-203 in Healthy Volunteers Acute Myeloid Leukemia	Phase 1	2010-01-01
Completed	Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Mali Advanced and Incurable Solid Tumors, Malignant Lymphomas	Phase 1	2010-01-01
Completed	Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma Hodgkin's Lymphoma	Phase 2	2009-12-01
Completed	SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Rheumatoid Arthritis	Phase 2	2009-11-01
Completed	4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma	Phase 2	2009-07-01
Completed	SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD)	Phase 2	2009-03-01